The Rosen Law Firm announced a deadline for investors who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities. Investors who bought stock during the class period, which runs from October 9, 2024, to July 10, 2025, may be entitled to compensation.
The firm alleges that Capricor misled investors about its lead drug candidate, deramiocel, a cell therapy for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). The complaint claims that Capricor‘s statements regarding the drug’s prospects, including the possibility of securing a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA), were overly optimistic and not supported by the available data.
Specifically, the lawsuit contends that Capricor downplayed or concealed negative data from its Phase 2 HOPE-2 trial regarding the safety and efficacy of deramiocel over a four-year period. This alleged misrepresentation, according to the Rosen Law Firm, artificially inflated the price of Capricor‘s stock, causing investors to suffer losses when the truth emerged.
The Rosen Law Firm encourages investors to consider their options. The firm emphasizes the importance of selecting legal counsel with a proven track record in securities class action litigation. They highlight their own extensive experience and success in recovering significant funds for investors, including a landmark settlement against a Chinese company. The firm points to its ranking by ISS Securities Class Action Services and its consistent placement among top firms in the field.
Investors who wish to participate in the class action must act before the September 15, 2025, deadline. This deadline applies to those seeking to serve as lead plaintiff, a representative who directs the litigation on behalf of all class members. However, participation in any potential recovery is not contingent on being named lead plaintiff.
Interested investors can contact Phillip Kim, Esq. at the Rosen Law Firm for more information. The firm stresses that no class has yet been certified, and individuals are not represented by counsel unless they retain one. They also have the option to remain absent class members. The information provided is for informational purposes only and constitutes attorney advertising. Past successes do not guarantee similar outcomes.
Related
